Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Baxter International Inc (BAX) vs Tempus AI (TEM) Price & Performance

Baxter International IncTrade

Price performance (Past 24H)

Key statistics

Baxter International Inc vs Tempus AI — how do they compare? Baxter International Inc trades at $27.61 (market cap $14.36B), while Tempus AI trades at $55.49 (market cap $9.93B). The key difference: Baxter International Inc is the larger of the two by market cap, and Baxter International Inc pays a 0.14% dividend while Tempus AI pays none. Which is the better fit depends on your goals.

BAXTEM
Market Cap
$14.36B$9.93B
Sector
HealthBroad Market / Factor
52-Week High
$28.35$103.25
52-Week Low
$15.80$41.55
Enterprise Value
$21.88B$10.56B
Dividend Yield
0.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Baxter International Inc

Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.

The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.

Tempus AI

Tempus AI (TEM) trades at $52.05, up 12.86% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat revenue estimates and raised 2026 sales guidance. The stock is technically bullish with moving averages supporting upside, while fundamentals show revenue growth to $1.4 billion in 2026 but persistent net losses. Recent news highlights expansion through the Personalis acquisition and AI-driven precision medicine advancements.

Outlook: Growth prospects are robust with AI adoption in healthcare and strategic deals, but high valuation ratios and negative profitability pose risks. Analysts are bullish with a $61.57 consensus target, though cash burn and competitive pressures require monitoring for sustained investor confidence.

Returns comparison

Trailing returns across standard periods

About Baxter International Inc

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.

Read more on BAX

About Tempus AI

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Read more on TEM